Marlene Leslie Durand, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endophthalmitis | 19 | 2017 | 263 | 3.100 |
Why?
|
| Eye Infections, Bacterial | 16 | 2023 | 235 | 1.960 |
Why?
|
| Free Tissue Flaps | 5 | 2018 | 320 | 1.730 |
Why?
|
| Surgical Wound Infection | 9 | 2021 | 1538 | 1.650 |
Why?
|
| Mycoses | 7 | 2017 | 376 | 1.540 |
Why?
|
| Keratitis | 5 | 2021 | 268 | 1.160 |
Why?
|
| Eye Infections | 3 | 2023 | 64 | 1.090 |
Why?
|
| Surgical Flaps | 4 | 2021 | 1634 | 1.060 |
Why?
|
| Eye Infections, Fungal | 8 | 2021 | 110 | 1.030 |
Why?
|
| Antibiotic Prophylaxis | 6 | 2016 | 638 | 1.030 |
Why?
|
| Prosthesis-Related Infections | 6 | 2016 | 538 | 0.960 |
Why?
|
| Bacterial Infections | 5 | 2017 | 1389 | 0.920 |
Why?
|
| Head and Neck Neoplasms | 8 | 2021 | 2712 | 0.910 |
Why?
|
| Herpes Zoster Ophthalmicus | 3 | 2021 | 36 | 0.900 |
Why?
|
| Aspergillosis | 3 | 2021 | 235 | 0.890 |
Why?
|
| Mucormycosis | 2 | 2021 | 97 | 0.870 |
Why?
|
| Anti-Bacterial Agents | 24 | 2020 | 7153 | 0.720 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 2 | 2016 | 21 | 0.710 |
Why?
|
| Sinusitis | 5 | 2021 | 922 | 0.690 |
Why?
|
| Eye Infections, Viral | 2 | 2016 | 57 | 0.640 |
Why?
|
| Vitrectomy | 9 | 2017 | 365 | 0.630 |
Why?
|
| Urinary Tract Infections | 2 | 2021 | 786 | 0.600 |
Why?
|
| Antifungal Agents | 7 | 2021 | 729 | 0.590 |
Why?
|
| Foscarnet | 1 | 2016 | 38 | 0.580 |
Why?
|
| Eye Infections, Parasitic | 3 | 2018 | 24 | 0.580 |
Why?
|
| Polymyxins | 1 | 2016 | 22 | 0.570 |
Why?
|
| Trimethoprim | 1 | 2016 | 91 | 0.550 |
Why?
|
| Cytosine | 1 | 2016 | 216 | 0.520 |
Why?
|
| Histoplasma | 1 | 2014 | 41 | 0.500 |
Why?
|
| Bacteria | 6 | 2017 | 2102 | 0.500 |
Why?
|
| Clostridium Infections | 1 | 2021 | 548 | 0.500 |
Why?
|
| Bacteremia | 1 | 2021 | 962 | 0.490 |
Why?
|
| Histoplasmosis | 1 | 2014 | 66 | 0.490 |
Why?
|
| Vitreous Body | 6 | 2016 | 389 | 0.480 |
Why?
|
| Cornea | 5 | 2010 | 1497 | 0.480 |
Why?
|
| Palatine Tonsil | 1 | 2014 | 193 | 0.470 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2015 | 349 | 0.470 |
Why?
|
| Pharyngeal Diseases | 1 | 2014 | 132 | 0.460 |
Why?
|
| Eye | 2 | 2023 | 728 | 0.460 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2016 | 312 | 0.450 |
Why?
|
| Herpes Simplex | 1 | 2016 | 466 | 0.450 |
Why?
|
| Microsurgery | 1 | 2018 | 796 | 0.420 |
Why?
|
| Orbital Cellulitis | 2 | 2009 | 33 | 0.400 |
Why?
|
| Toxocara | 1 | 2011 | 1 | 0.400 |
Why?
|
| Laryngeal Diseases | 1 | 2014 | 241 | 0.400 |
Why?
|
| Toxocariasis | 1 | 2011 | 11 | 0.390 |
Why?
|
| Triazoles | 3 | 2021 | 907 | 0.390 |
Why?
|
| Antiparasitic Agents | 1 | 2011 | 41 | 0.380 |
Why?
|
| Clindamycin | 2 | 2016 | 139 | 0.380 |
Why?
|
| Eyelid Diseases | 3 | 2018 | 155 | 0.360 |
Why?
|
| Aqueous Humor | 2 | 2010 | 161 | 0.360 |
Why?
|
| Ethmoid Sinus | 1 | 2010 | 58 | 0.360 |
Why?
|
| Pneumonia | 1 | 2021 | 2117 | 0.350 |
Why?
|
| Vancomycin | 2 | 2011 | 500 | 0.350 |
Why?
|
| Corneal Ulcer | 4 | 2016 | 169 | 0.340 |
Why?
|
| Fusarium | 2 | 2007 | 51 | 0.330 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2010 | 116 | 0.320 |
Why?
|
| Maxillary Sinus | 1 | 2010 | 180 | 0.320 |
Why?
|
| Abscess | 2 | 2010 | 607 | 0.320 |
Why?
|
| Lacrimal Apparatus | 1 | 2010 | 224 | 0.310 |
Why?
|
| Dacryocystitis | 1 | 2008 | 69 | 0.310 |
Why?
|
| Orbital Diseases | 4 | 2015 | 181 | 0.310 |
Why?
|
| Artificial Organs | 1 | 2010 | 204 | 0.310 |
Why?
|
| Prosthesis Implantation | 3 | 2009 | 641 | 0.300 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2008 | 232 | 0.300 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2009 | 115 | 0.290 |
Why?
|
| Antiviral Agents | 3 | 2016 | 2978 | 0.290 |
Why?
|
| Syphilis | 3 | 2016 | 226 | 0.270 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 687 | 0.270 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 1194 | 0.270 |
Why?
|
| Contact Lenses | 2 | 2021 | 145 | 0.270 |
Why?
|
| Fungi | 3 | 2017 | 327 | 0.260 |
Why?
|
| Herpesvirus 3, Human | 2 | 2016 | 204 | 0.250 |
Why?
|
| Aspergillus fumigatus | 1 | 2005 | 150 | 0.240 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 637 | 0.230 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2004 | 79 | 0.230 |
Why?
|
| Drug Therapy, Combination | 7 | 2007 | 6483 | 0.230 |
Why?
|
| Facial Paralysis | 2 | 2021 | 338 | 0.230 |
Why?
|
| Staphylococcal Infections | 4 | 2016 | 1398 | 0.230 |
Why?
|
| Patient Readmission | 1 | 2017 | 3111 | 0.230 |
Why?
|
| Postoperative Complications | 8 | 2017 | 15244 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2015 | 1032 | 0.220 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 401 | 0.220 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2015 | 341 | 0.220 |
Why?
|
| Retrospective Studies | 20 | 2021 | 77098 | 0.220 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 289 | 0.210 |
Why?
|
| Acanthamoeba Keratitis | 1 | 2021 | 17 | 0.200 |
Why?
|
| Eye Evisceration | 2 | 2013 | 22 | 0.200 |
Why?
|
| Humans | 74 | 2023 | 742088 | 0.200 |
Why?
|
| Bell Palsy | 1 | 2021 | 42 | 0.200 |
Why?
|
| Achromobacter | 1 | 2021 | 7 | 0.200 |
Why?
|
| Keratitis, Herpetic | 1 | 2021 | 81 | 0.190 |
Why?
|
| Organ Preservation Solutions | 1 | 2021 | 94 | 0.190 |
Why?
|
| Cataract Extraction | 4 | 2012 | 482 | 0.190 |
Why?
|
| Aged | 26 | 2018 | 162944 | 0.180 |
Why?
|
| Drug Contamination | 1 | 2021 | 148 | 0.180 |
Why?
|
| Ophthalmic Solutions | 1 | 2021 | 313 | 0.180 |
Why?
|
| Massachusetts | 3 | 2017 | 8662 | 0.170 |
Why?
|
| Limbus Corneae | 1 | 2021 | 142 | 0.170 |
Why?
|
| Risk Factors | 14 | 2021 | 72145 | 0.170 |
Why?
|
| Middle Aged | 34 | 2017 | 213127 | 0.170 |
Why?
|
| Incidence | 8 | 2016 | 20928 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2021 | 252 | 0.160 |
Why?
|
| Simuliidae | 1 | 1998 | 4 | 0.160 |
Why?
|
| Onchocerciasis, Ocular | 1 | 1998 | 7 | 0.160 |
Why?
|
| Myiasis | 1 | 2018 | 15 | 0.160 |
Why?
|
| Onchocerca volvulus | 1 | 1998 | 12 | 0.160 |
Why?
|
| Administration, Topical | 2 | 2016 | 688 | 0.160 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 2271 | 0.160 |
Why?
|
| Glossectomy | 1 | 2018 | 58 | 0.160 |
Why?
|
| Diptera | 1 | 2018 | 53 | 0.150 |
Why?
|
| Anti-Infective Agents | 3 | 2013 | 971 | 0.150 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 8621 | 0.150 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 39004 | 0.150 |
Why?
|
| Visual Acuity | 3 | 2009 | 2520 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2021 | 1871 | 0.140 |
Why?
|
| Nitriles | 1 | 2021 | 952 | 0.140 |
Why?
|
| Actinomycetaceae | 1 | 2015 | 5 | 0.140 |
Why?
|
| Cutaneous Fistula | 1 | 2016 | 78 | 0.140 |
Why?
|
| Eye Enucleation | 2 | 2013 | 128 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 179 | 0.140 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2015 | 29 | 0.130 |
Why?
|
| Eyelids | 1 | 2018 | 263 | 0.130 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1996 | 65 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2014 | 23320 | 0.130 |
Why?
|
| Eye Diseases | 3 | 2009 | 670 | 0.130 |
Why?
|
| Paecilomyces | 1 | 2014 | 3 | 0.130 |
Why?
|
| Intravitreal Injections | 2 | 2015 | 345 | 0.120 |
Why?
|
| beta-Lactamases | 1 | 2016 | 303 | 0.120 |
Why?
|
| Keratoplasty, Penetrating | 4 | 2021 | 154 | 0.120 |
Why?
|
| Otolaryngology | 1 | 2021 | 644 | 0.120 |
Why?
|
| Conjunctivitis | 1 | 1996 | 158 | 0.120 |
Why?
|
| Toxoplasma | 1 | 2015 | 150 | 0.120 |
Why?
|
| Antibodies, Protozoan | 1 | 2015 | 253 | 0.120 |
Why?
|
| Oropharynx | 1 | 2014 | 127 | 0.120 |
Why?
|
| Optic Neuritis | 1 | 2016 | 166 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2005 | 2933 | 0.110 |
Why?
|
| Rhinitis | 1 | 2020 | 691 | 0.110 |
Why?
|
| Lymphopenia | 1 | 2015 | 285 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 6171 | 0.110 |
Why?
|
| Male | 36 | 2018 | 349538 | 0.110 |
Why?
|
| Corneal Diseases | 3 | 2010 | 615 | 0.110 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 1449 | 0.110 |
Why?
|
| Length of Stay | 2 | 2016 | 6294 | 0.110 |
Why?
|
| Pharyngitis | 1 | 2014 | 215 | 0.110 |
Why?
|
| Simplexvirus | 1 | 2016 | 802 | 0.110 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 532 | 0.110 |
Why?
|
| Device Removal | 1 | 2018 | 652 | 0.110 |
Why?
|
| Diagnosis, Differential | 8 | 2016 | 12958 | 0.110 |
Why?
|
| Debridement | 3 | 2015 | 492 | 0.110 |
Why?
|
| Female | 29 | 2018 | 379592 | 0.110 |
Why?
|
| Wound Healing | 3 | 2018 | 2781 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1640 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2016 | 563 | 0.100 |
Why?
|
| Young Adult | 11 | 2017 | 56350 | 0.100 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2009 | 277 | 0.100 |
Why?
|
| Exanthema | 1 | 2016 | 488 | 0.100 |
Why?
|
| Pythium | 1 | 2011 | 5 | 0.100 |
Why?
|
| Pythiosis | 1 | 2011 | 5 | 0.100 |
Why?
|
| Bioprosthesis | 1 | 2016 | 596 | 0.100 |
Why?
|
| Sulfadiazine | 1 | 2010 | 18 | 0.100 |
Why?
|
| Eye Burns | 2 | 2009 | 102 | 0.100 |
Why?
|
| Aspergillus niger | 1 | 2010 | 17 | 0.100 |
Why?
|
| Reoperation | 3 | 2018 | 4200 | 0.100 |
Why?
|
| Meningitis, Bacterial | 1 | 1993 | 218 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 4029 | 0.090 |
Why?
|
| Vancomycin Resistance | 1 | 2011 | 128 | 0.090 |
Why?
|
| Virulence | 3 | 2016 | 1328 | 0.090 |
Why?
|
| Retropharyngeal Abscess | 1 | 2010 | 21 | 0.090 |
Why?
|
| Gram-Positive Cocci | 1 | 2009 | 9 | 0.090 |
Why?
|
| Eye Injuries | 1 | 2013 | 245 | 0.090 |
Why?
|
| Adult | 23 | 2020 | 213712 | 0.090 |
Why?
|
| Pyridines | 1 | 2021 | 2818 | 0.090 |
Why?
|
| Virus Diseases | 1 | 1996 | 710 | 0.090 |
Why?
|
| Haemophilus paraphrophilus | 1 | 2008 | 2 | 0.080 |
Why?
|
| Eikenella corrodens | 1 | 2008 | 18 | 0.080 |
Why?
|
| Aneurysm, Infected | 1 | 2009 | 85 | 0.080 |
Why?
|
| Streptococcus anginosus | 1 | 2008 | 24 | 0.080 |
Why?
|
| Crowns | 1 | 2009 | 152 | 0.080 |
Why?
|
| Addison Disease | 1 | 2009 | 48 | 0.080 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2009 | 123 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2011 | 319 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2020 | 9144 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2020 | 62966 | 0.080 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 57683 | 0.080 |
Why?
|
| Hearing Loss, Sudden | 1 | 2008 | 43 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 847 | 0.080 |
Why?
|
| Temporal Arteries | 1 | 2008 | 128 | 0.080 |
Why?
|
| Streptococcus agalactiae | 1 | 2009 | 375 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1237 | 0.070 |
Why?
|
| Alternaria | 1 | 2007 | 44 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2009 | 445 | 0.070 |
Why?
|
| Dura Mater | 1 | 2008 | 291 | 0.070 |
Why?
|
| Focal Infection, Dental | 1 | 2006 | 24 | 0.070 |
Why?
|
| Drainage | 2 | 2010 | 1140 | 0.070 |
Why?
|
| Candida | 1 | 2007 | 172 | 0.070 |
Why?
|
| Prostheses and Implants | 2 | 2005 | 1385 | 0.070 |
Why?
|
| Echinocandins | 1 | 2005 | 44 | 0.070 |
Why?
|
| Orbit Evisceration | 1 | 2005 | 8 | 0.070 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 368 | 0.070 |
Why?
|
| Leishmaniasis, Mucocutaneous | 1 | 2005 | 12 | 0.070 |
Why?
|
| Leishmania braziliensis | 1 | 2005 | 15 | 0.070 |
Why?
|
| Lipopeptides | 1 | 2005 | 75 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6534 | 0.060 |
Why?
|
| Granuloma, Pyogenic | 1 | 2005 | 48 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2266 | 0.060 |
Why?
|
| Meningitis, Meningococcal | 1 | 2004 | 43 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 2211 | 0.060 |
Why?
|
| Glucocorticoids | 3 | 2009 | 2107 | 0.060 |
Why?
|
| Giant Cell Arteritis | 1 | 2008 | 292 | 0.060 |
Why?
|
| Keratoconjunctivitis | 1 | 2004 | 53 | 0.060 |
Why?
|
| Neisseria meningitidis | 1 | 2004 | 109 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2016 | 4214 | 0.060 |
Why?
|
| Cellulitis | 1 | 2006 | 206 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 6756 | 0.060 |
Why?
|
| Intraocular Pressure | 1 | 2010 | 1274 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11363 | 0.060 |
Why?
|
| Cicatrix | 1 | 2009 | 761 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4554 | 0.060 |
Why?
|
| Cross Infection | 1 | 1993 | 1413 | 0.060 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2005 | 193 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 4379 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 40054 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2763 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2010 | 897 | 0.050 |
Why?
|
| Uveitis | 2 | 2016 | 375 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 854 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2008 | 770 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2009 | 1949 | 0.050 |
Why?
|
| Eye Banks | 1 | 2021 | 19 | 0.050 |
Why?
|
| Adolescent | 8 | 2015 | 85649 | 0.050 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2001 | 15 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3839 | 0.050 |
Why?
|
| Equipment Design | 1 | 2009 | 3582 | 0.050 |
Why?
|
| Diabetic Foot | 1 | 2004 | 352 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 4147 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2010 | 20086 | 0.050 |
Why?
|
| Glaucoma | 1 | 2010 | 1152 | 0.050 |
Why?
|
| Candida albicans | 2 | 2001 | 394 | 0.050 |
Why?
|
| DNA, Ribosomal | 1 | 2021 | 289 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2021 | 276 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 1606 | 0.040 |
Why?
|
| Prevalence | 2 | 2011 | 15194 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2017 | 40450 | 0.040 |
Why?
|
| Vision, Monocular | 1 | 1999 | 78 | 0.040 |
Why?
|
| Mycobacterium Infections | 1 | 1999 | 119 | 0.040 |
Why?
|
| Candidiasis | 1 | 2001 | 365 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 2951 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2021 | 355 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 1997 | 153 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 947 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2015 | 2557 | 0.040 |
Why?
|
| Anterior Eye Segment | 1 | 1998 | 153 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 1 | 1997 | 256 | 0.040 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2016 | 35 | 0.040 |
Why?
|
| Latin America | 1 | 1998 | 381 | 0.040 |
Why?
|
| HIV Infections | 3 | 2016 | 16678 | 0.040 |
Why?
|
| Vision Disorders | 2 | 2016 | 1057 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 657 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2009 | 4393 | 0.030 |
Why?
|
| Neurosyphilis | 1 | 2016 | 22 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2014 | 3913 | 0.030 |
Why?
|
| Africa | 1 | 1998 | 670 | 0.030 |
Why?
|
| Chorioretinitis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Anterior Chamber | 2 | 2011 | 195 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 1998 | 294 | 0.030 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2016 | 51 | 0.030 |
Why?
|
| Mucorales | 1 | 2015 | 33 | 0.030 |
Why?
|
| Aspergillus | 1 | 2015 | 85 | 0.030 |
Why?
|
| Child | 6 | 2021 | 77478 | 0.030 |
Why?
|
| Acyclovir | 1 | 2015 | 272 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2021 | 2205 | 0.030 |
Why?
|
| Argentina | 1 | 2015 | 232 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 357 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 211 | 0.030 |
Why?
|
| Lenses, Intraocular | 1 | 1996 | 142 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2016 | 538 | 0.030 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2015 | 163 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3695 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 654 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 230 | 0.030 |
Why?
|
| Valine | 1 | 2015 | 413 | 0.030 |
Why?
|
| Arthritis, Psoriatic | 1 | 2016 | 215 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 828 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1996 | 860 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5425 | 0.030 |
Why?
|
| HIV-1 | 1 | 2010 | 6934 | 0.030 |
Why?
|
| Neuromyelitis Optica | 1 | 2016 | 253 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15056 | 0.030 |
Why?
|
| Suppuration | 1 | 2011 | 56 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2015 | 936 | 0.020 |
Why?
|
| Fever | 2 | 2009 | 1612 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2010 | 40955 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2016 | 1538 | 0.020 |
Why?
|
| Endoscopy | 1 | 2020 | 1774 | 0.020 |
Why?
|
| Uveitis, Posterior | 1 | 2010 | 44 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1184 | 0.020 |
Why?
|
| United States | 3 | 2016 | 69693 | 0.020 |
Why?
|
| Cardiolipins | 1 | 2010 | 88 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15530 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2016 | 503 | 0.020 |
Why?
|
| Recurrence | 2 | 2011 | 8333 | 0.020 |
Why?
|
| Canada | 1 | 2015 | 2061 | 0.020 |
Why?
|
| Internationality | 1 | 2015 | 1002 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 2010 | 472 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2015 | 2970 | 0.020 |
Why?
|
| Ophthalmology | 1 | 2015 | 506 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 230 | 0.020 |
Why?
|
| Polyuria | 1 | 2008 | 39 | 0.020 |
Why?
|
| India | 1 | 2015 | 2187 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2016 | 765 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2010 | 411 | 0.020 |
Why?
|
| Animals | 4 | 2018 | 168561 | 0.020 |
Why?
|
| Urinalysis | 1 | 2010 | 369 | 0.020 |
Why?
|
| Israel | 1 | 2011 | 795 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3862 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1993 | 496 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2015 | 2451 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 534 | 0.020 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2008 | 204 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 35070 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 14720 | 0.020 |
Why?
|
| Steroids | 1 | 2012 | 931 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2008 | 281 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 1484 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2000 | 5978 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1583 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2008 | 364 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 2009 | 531 | 0.020 |
Why?
|
| Cochlear Nerve | 1 | 2008 | 197 | 0.020 |
Why?
|
| Nafcillin | 1 | 2005 | 25 | 0.020 |
Why?
|
| Antimony Sodium Gluconate | 1 | 2005 | 10 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 6452 | 0.020 |
Why?
|
| Trypanocidal Agents | 1 | 2005 | 38 | 0.020 |
Why?
|
| Boston | 2 | 2001 | 9305 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2005 | 145 | 0.020 |
Why?
|
| Nose Diseases | 1 | 2005 | 79 | 0.020 |
Why?
|
| Conjunctival Neoplasms | 1 | 2005 | 79 | 0.020 |
Why?
|
| Burns, Chemical | 1 | 2005 | 154 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 2008 | 557 | 0.010 |
Why?
|
| Prednisone | 1 | 2008 | 1567 | 0.010 |
Why?
|
| Bone Cements | 1 | 2005 | 325 | 0.010 |
Why?
|
| Ceftriaxone | 1 | 2004 | 168 | 0.010 |
Why?
|
| Hospital Mortality | 2 | 1997 | 5310 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 2637 | 0.010 |
Why?
|
| Nasal Obstruction | 1 | 2005 | 151 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9846 | 0.010 |
Why?
|
| Injections | 1 | 2005 | 840 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 7141 | 0.010 |
Why?
|
| Penicillins | 1 | 2004 | 378 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2010 | 2899 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 1872 | 0.010 |
Why?
|
| Pain | 2 | 2009 | 4961 | 0.010 |
Why?
|
| Cholesterol | 1 | 2010 | 2895 | 0.010 |
Why?
|
| Nose | 1 | 2005 | 509 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 53187 | 0.010 |
Why?
|
| Amphotericin B | 1 | 2001 | 137 | 0.010 |
Why?
|
| Headache | 1 | 2008 | 1219 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 1473 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1996 | 7901 | 0.010 |
Why?
|
| Seizures | 1 | 1993 | 2851 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 2001 | 184 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4801 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 12730 | 0.010 |
Why?
|
| Amikacin | 1 | 1999 | 48 | 0.010 |
Why?
|
| Asthma | 1 | 1997 | 5955 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8297 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 35342 | 0.010 |
Why?
|
| Status Asthmaticus | 1 | 1997 | 22 | 0.010 |
Why?
|
| Sympathomimetics | 1 | 1997 | 57 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 2010 | 1967 | 0.010 |
Why?
|
| Azithromycin | 1 | 1999 | 195 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 7010 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1999 | 249 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3612 | 0.010 |
Why?
|
| France | 1 | 1997 | 517 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 346 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29010 | 0.010 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2008 | 1808 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 24913 | 0.010 |
Why?
|
| Disease Progression | 1 | 2011 | 13256 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 533 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 3678 | 0.010 |
Why?
|
| Dyspnea | 1 | 1997 | 1298 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 2948 | 0.010 |
Why?
|
| Brain | 2 | 2008 | 26343 | 0.010 |
Why?
|
| Cause of Death | 1 | 1997 | 3571 | 0.000 |
Why?
|
| Melanoma | 1 | 2005 | 5462 | 0.000 |
Why?
|
| Critical Care | 1 | 1997 | 2640 | 0.000 |
Why?
|
| Survival Rate | 1 | 1997 | 12773 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1997 | 12344 | 0.000 |
Why?
|
| Age Factors | 1 | 1997 | 18355 | 0.000 |
Why?
|
| Hospitalization | 1 | 1997 | 10232 | 0.000 |
Why?
|